Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is based on Arecor’s proprietary Arestat™ technology platform.
Advancing today's therapies to enable healthier lives.
Telephone: +44 (0)1223 426 060
Chesterford Research Park Little Chesterford Saffron Walden
Post Code: CB10 1XL
Country: United Kingdom
Membership Type: Corporate 21-50